Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002050 · ClinicalTrials.gov registry record · NA
A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients
A NA study, sponsored by Immunobiology Research Institute.
- Completed
- Registry status
- NA
- Development phase
NCT00002050: Completed NA study, sponsored by Immunobiology Research Institute.
NCT00002050 is a NA study that has completed, run by Immunobiology Research Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002050, a NA study, has completed, sponsored by Immunobiology Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.
Interventions
- DRUG Thymopentin
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002050
The ClinicalTrials.gov registry entry for NCT00002050 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Immunobiology Research Institute, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thymopentin is the first listed.
NCT00002050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002050 about?
NCT00002050 is a clinical study titled "A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients". Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.
What is the current status of trial NCT00002050?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002050?
The interventions under investigation include: Thymopentin (DRUG).
Who is sponsoring clinical trial NCT00002050?
This trial is sponsored by Immunobiology Research Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.